Legacy Education Posts Record FY26 with 25% Revenue Growth but Slower than Q1

What happened

Legacy Education reported record fiscal 2026 results with 25% revenue growth and continued enrollment gains, building on the strong momentum from Q1 FY26. The full-year growth of 25% indicates a deceleration from the 38.5% revenue growth reported in Q1 FY26, suggesting the growth rate is normalizing as the company scales. The results likely reflect contributions from the CCMCC acquisition and new program launches across its healthcare-focused campuses. However, the company's heavy reliance on Title IV funding and regulatory overhang in the for-profit education sector remain significant risks. Investors should await full financial details to assess whether profitability and cash flow kept pace with revenue growth.

Implication

Investors should view the 25% full-year revenue growth as positive but note the moderation from Q1's 38.5%, indicating that growth may be maturing. The enrollment gains are encouraging for future revenue, but the key question is whether EBITDA margins held steady or improved amid scaling costs. Given the company's net cash position and modest valuation, the stock remains attractive for risk-tolerant investors, but regulatory risks and volatile free cash flow warrant a small position size. Any deterioration in student outcomes, accreditation status, or Title IV eligibility would quickly invalidate the thesis. Until detailed FY26 financials and updated regulatory signals emerge, maintaining a cautious stance with a 'POSSIBLE BUY' rating is prudent.

Thesis delta

The thesis shifts modestly positive as full-year FY26 results confirm sustained double-digit revenue growth and enrollment expansion, reinforcing the demand story. However, the deceleration from Q1's 38.5% to full-year 25% and the absence of detailed margin and cash flow data prevent a full upgrade. The core investment case of a niche healthcare educator with a strong balance sheet remains intact, but regulatory and execution risks persist, so the judgment stays at 'POSSIBLE BUY' pending further financial disclosure.